[go: up one dir, main page]

PL1981504T3 - Pochodne tiadiazolu do leczenia chorób neurodegeneracyjnych - Google Patents

Pochodne tiadiazolu do leczenia chorób neurodegeneracyjnych

Info

Publication number
PL1981504T3
PL1981504T3 PL07711455T PL07711455T PL1981504T3 PL 1981504 T3 PL1981504 T3 PL 1981504T3 PL 07711455 T PL07711455 T PL 07711455T PL 07711455 T PL07711455 T PL 07711455T PL 1981504 T3 PL1981504 T3 PL 1981504T3
Authority
PL
Poland
Prior art keywords
treatment
disease
thiadiazole derivatives
degenerative diseases
neuro degenerative
Prior art date
Application number
PL07711455T
Other languages
English (en)
Inventor
Gerard Griffioen
Kristel Marie Edith Coupet
Hein Roger Duhamel
Stefaan Wera
Ellen Gomme
Damme Nele Van
Der Auwera Ingrid Van
Marleen Lox
Dooren Tom Van
Tine Decruy
Original Assignee
Nv Remynd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nv Remynd filed Critical Nv Remynd
Publication of PL1981504T3 publication Critical patent/PL1981504T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07711455T 2006-02-07 2007-02-07 Pochodne tiadiazolu do leczenia chorób neurodegeneracyjnych PL1981504T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0602335.2A GB0602335D0 (en) 2006-02-07 2006-02-07 Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
EP07711455A EP1981504B1 (en) 2006-02-07 2007-02-07 Thiadiazole derivatives for the treatment of neuro degenerative diseases
PCT/EP2007/001022 WO2007090617A2 (en) 2006-02-07 2007-02-07 Thiadiazole derivatives for the treatment of neuro degenerative diseases

Publications (1)

Publication Number Publication Date
PL1981504T3 true PL1981504T3 (pl) 2010-12-31

Family

ID=36101115

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07711455T PL1981504T3 (pl) 2006-02-07 2007-02-07 Pochodne tiadiazolu do leczenia chorób neurodegeneracyjnych

Country Status (15)

Country Link
EP (1) EP1981504B1 (pl)
JP (1) JP5283511B2 (pl)
CN (1) CN101378757B (pl)
AT (1) ATE474579T1 (pl)
AU (1) AU2007213954B2 (pl)
BR (1) BRPI0707700B8 (pl)
CA (1) CA2641453C (pl)
DE (1) DE602007007890D1 (pl)
DK (1) DK1981504T3 (pl)
EA (1) EA018067B1 (pl)
ES (1) ES2348999T3 (pl)
GB (1) GB0602335D0 (pl)
PL (1) PL1981504T3 (pl)
PT (1) PT1981504E (pl)
WO (1) WO2007090617A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
US20090325964A1 (en) * 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
WO2009156098A2 (de) * 2008-06-27 2009-12-30 Bayer Cropscience Ag Thiadiazolyloxyphenylamidine und deren verwendung als fungizide
EP2427637B1 (en) 2009-05-04 2017-03-08 BASF Corporation Improved lean hc conversion of twc for lean burn gasoline engines
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
PL2726470T3 (pl) * 2011-07-01 2015-09-30 Remynd Nv Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
US9187440B2 (en) 2011-08-17 2015-11-17 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
LT3083616T (lt) 2013-12-20 2021-09-10 Astex Therapeutics Limited Bicikinių heterociklų junginiai ir jų panaudojimas terapijoje
EP3119774A1 (en) * 2014-03-17 2017-01-25 reMynd NV Oxadiazole compounds
JP2023538326A (ja) * 2020-08-11 2023-09-07 ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティ プロテアソームエンハンサ及びその使用
WO2025104092A1 (en) 2023-11-13 2025-05-22 Remynd N.V. Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060472A (en) 1998-04-06 2000-05-09 Apotex Inc. Thiadiazole compounds useful as inhibitors of H+ /K+ atpase
WO2002083863A2 (en) * 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
WO2005020991A1 (en) * 2003-08-21 2005-03-10 Pfizer Products, Inc. Compounds for the treatment of neurodegenerative disorders
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
AU2007213954B2 (en) 2011-09-22
CA2641453A1 (en) 2007-08-16
HK1122989A1 (en) 2009-06-05
EA200870233A1 (ru) 2009-02-27
BRPI0707700B1 (pt) 2020-08-04
CA2641453C (en) 2013-07-30
CN101378757A (zh) 2009-03-04
EP1981504A2 (en) 2008-10-22
WO2007090617A3 (en) 2008-02-28
JP5283511B2 (ja) 2013-09-04
WO2007090617A2 (en) 2007-08-16
EP1981504B1 (en) 2010-07-21
GB0602335D0 (en) 2006-03-15
DK1981504T3 (da) 2010-11-08
PT1981504E (pt) 2010-10-13
JP2009526000A (ja) 2009-07-16
DE602007007890D1 (de) 2010-09-02
AU2007213954A1 (en) 2007-08-16
ATE474579T1 (de) 2010-08-15
BRPI0707700A2 (pt) 2011-05-10
ES2348999T3 (es) 2010-12-21
CN101378757B (zh) 2012-08-01
BRPI0707700B8 (pt) 2022-12-20
EA018067B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
PL1981504T3 (pl) Pochodne tiadiazolu do leczenia chorób neurodegeneracyjnych
MX2009007136A (es) Metodos para suministrar moleculas y objetivos de enlace especificos de enfermedades.
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
MY150558A (en) A pharmaceutical composition comprising rebamipide
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007150077A8 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
IL202158A (en) History of Oxadiazole, Pharmaceuticals Containing Them and Their Use in the manufacture of Drugs for the Treatment of Neurological and Psychiatric Disorders
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
MY162640A (en) Thioninium compounds and their use
WO2009019295A3 (en) Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases
MX2010013451A (es) Composiciones farmaceuticas que comprenden derivados de aminociclohexano.
MX340564B (es) Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
WO2022204362A3 (en) Compositions and methods for treating a neurodegenerative or developmental disorder
IL198202A0 (en) Peptide-cytotoxic conjugates
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
KR102467285B9 (ko) 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
IL202221A (en) Transdermal Preparation of 1- (Benzoforan-2-Il) -2-Propylaminopentane for the Treatment of Alzheimer's, Parkinson's, Depression, Psychosis and Drug Dependence
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
UA95780C2 (en) Xanthine derivatives as selective hm74a agonists
WO2009140649A8 (en) Rab3b for the treatment and prevention of parkinson's disease
WO2008014232A3 (en) Pharmaceutical formulations for the treatment of alzheimer's disease
WO2008112701A3 (en) G-substrate for the treatment and prevention of parkinson's disease